Zynerba Pharmaceuticals Stock News

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced an oral presentation at the Society for the Study of Behavioural Phenotypes' 24th International Research Symposium, being held in Oslo, Norway,

DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi

Gainers Micro Focus International plc (NYSE: MFGP) shares rose 93.6% to $6.06 in pre-market trading after the company reached an agreement with Open Text Corporation (NASDAQ: OTEX) to be acquired fo

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will co

Canaccord Genuity (TSX:CF, LSE:CF) analysts have reiterated a 'Buy' rating and issued an $11 price target for Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc in a note to clients.  The brokerage firm rece

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported financial results for the second quarter ended June 30, 2022, and provided an overview of its recent operational highlights and a pipeline update

DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych

DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it has entered into an equity purchase agreement for up to $20 million with Chicago-based institutional investor Lincoln Park Capital Fund LLC (LPC), in

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced positive top-line results from the Phase 2 INSPIRE trial of Zygel (Transdermal CBD gel) on pediatric behavioral and emotional symptoms of 22q11.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced “very encouraging” data from a trial of its Zygel CBD gel for the treatment of 22q11.2 Deletion Syndrome (22q).  The exploratory, open-labe

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments –

Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc

Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc